Blocking Cannabinoid Receptors in Newborn Mice Produced ADHD and Tourette-Like Behaviors

Postnatal exposure to the CB1 blocker rimonabant in wild-type, CB1 knockout, and CB2 knockout mice produced distinct behavioral outcomes. Wild-type pups developed vocal-like tics and learning deficits; as adults, they showed hyperactivity, motor tics, and risky behavior. Vocal tics required both disrupted CB1 signaling and functional CB2 receptors. The findings suggest ADHD/Tourette syndrome may share a common origin in early cannabinoid system disruption.

Postnatal wild-type, CB1 knockout, and CB2 knockout mouse pups were exposed to rimonabant (CB1 antagonist/inverse agonist). Behavioral assessments tracked vocal tics, motor activity, learning, rearing, and risk-taking from postnatal period through adulthood. Sex-specific outcomes were analyzed across all genotypes.

If the endocannabinoid system plays a foundational role in neurodevelopment, disruptions during critical early periods could have lasting behavioral consequences. The sex-specific patterns (males more affected) mirror the clinical epidemiology of ADHD and Tourette syndrome.

ADHD and Tourette syndrome frequently co-occur in clinical practice but are typically treated as separate conditions. This research proposes they may represent a single phenotype arising from early endocannabinoid system dysfunction.

Mouse behavioral models have limited translational value for complex human neurodevelopmental disorders. Pharmacological disruption of cannabinoid signaling does not replicate naturally occurring developmental variations. Small sample sizes typical of transgenic mouse studies.